Valeant Will Become Bausch Health Companies Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Valeant Pharmaceuticals (VRX): 'A Turnaround For The Ages' - Cantor Fitzgerald
May 8, 2018 2:15 PM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $25 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q1 beat and raise.
"We think a greater appreciation for Valeant's solid execution and future growth prospects should drive upwards earnings revisions as well as multiple expansion in 2019+,"... More
